<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592501</url>
  </required_header>
  <id_info>
    <org_study_id>05-089</org_study_id>
    <nct_id>NCT00592501</nct_id>
  </id_info>
  <brief_title>Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Phase II Study of Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Photon beam radiation is the standard type of radiation used to treat nasopharyngeal&#xD;
      carcinoma. Photon beam radiation enters the body and passes through healthy tissue,&#xD;
      encounters the tumor and leaves the body through healthy tissue. Proton beam radiation has&#xD;
      been shown to have the same effect on tumors as photon beam radiation but it enters the body,&#xD;
      passes through healthy tissue, and encounters the tumor but then stops. This means less&#xD;
      healthy tissue is affected by proton beam treatment than by photon beam treatment. The&#xD;
      purpose of this study is to determine the effectiveness of proton beam radiation in treating&#xD;
      nasopharyngeal cancer and reducing the acute and long-term side effects from the treatment.&#xD;
      This study will also test to see if the sparing of the healthy tissue can improve quality of&#xD;
      life&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Before beginning study treatment, participants will be asked to fill out a Quality of&#xD;
           Life (QOL) questionnaires, a Speech Assessment, a ChemoSensory Questionnaire, a Patient&#xD;
           Swallowing Diary, A Swallowing Study, Salivary Tests and a Trismus Assessment.&#xD;
           Participants will need to go to the Massachusetts Eye and Ear Infirmary (MEEI) or&#xD;
           Massachusetts General Hospital (MGH) for these tests.&#xD;
&#xD;
        -  Radiation therapy will be given once a day, five days a week, for seven weeks. This will&#xD;
           be given as outpatient care at the Northeast Proton Therapy Center (proton component)&#xD;
           and Massachusetts General Hospital (photon component).&#xD;
&#xD;
        -  During radiation treatments, participants will receive cisplatin intravenously once&#xD;
           every three weeks. This three-week period is called a cycle of treatment.&#xD;
&#xD;
        -  After the completion of radiation, participants will receive cisplatin intravenously&#xD;
           once every 4 weeks along with fluorouracil as a continuous infusion over 4 days starting&#xD;
           on the day cisplatin is given, for three cycles.&#xD;
&#xD;
        -  Participants will have a physical exam and blood work drawn weekly to monitor their&#xD;
           health.&#xD;
&#xD;
        -  An MR/CT scan of the head and neck will be done 2 months after the radiation treatment.&#xD;
&#xD;
        -  Follow-up visits will occur once every three months for 2 years, then once every 6&#xD;
           months during years 3-5, then annually. During these follow-up visits, participants will&#xD;
           have the following tests and procedures: physical examination; blood work; chest CT scan&#xD;
           and CT/MRI of the head and neck will be repeated once every 6 months during the first&#xD;
           three years; swallow study; salivary study; QOL questionnaires; speech assessment;&#xD;
           ChemoSensory Questionnaire; and Trismus Assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Acute Toxicity</measure>
    <time_frame>54 days of chemoradiation treatment and 90 days after completion, up to 144 days total</time_frame>
    <description>Acute toxicities are side affects that occur during treatment and 90 days after completion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Compliance Rate to Assigned Treatment Intervention</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sialometry to Evaluate Xerostomia (Dry Mouth)</measure>
    <time_frame>Baseline and 2 years (24 months)</time_frame>
    <description>Sialometry is a measure of saliva flow. The normal daily production of saliva varies between 0.5 and 1.5 liters. Stimulated saliva is produced in response to a mechanical, gustatory, olfactory, or pharmacological stimulus, contributing to around 40-50% of daily salivary production. In adults, normal total stimulated salivary flow ranges 1-3 mL/minute, low ranges 0.7-1.0 mL/minute, while hyposalivation is characterized by a stimulated salivary flow &lt;0.7mL/minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penetration-aspiration Scale to Evaluate Swallowing Function</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The videofluoroscopic swallow study (VFSS) is the gold standard diagnostic tool to evaluate oropharyngeal dysphagia. The penetration-aspiration scale (PAS) is an 8-point scale used to grade the severity of penetration or aspiration observed in a videofluoroscopic swallow study. Aspiration is defined as the passing of the bolus below the true vocal folds, and penetration is when the bolus enters the airway but not below the true vocal folds. 1 is normal, no penetration or aspiration. 2-5 is penetration. 6-8 is aspiration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serial Measurements of Maximal Inter-incisal Distance to Evaluate Trismus (Lockjaw)</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Serial measures of the changes of the maximal inter-incisal distance in the vertical opening, right lateral, and left lateral jaw movements are used to evaluate trismus (lockjaw). An average measurement of the three directional areas will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ChemoSensory Questionnaire (CSQ) to Evaluate Smell and Taste Function</measure>
    <time_frame>2 years</time_frame>
    <description>The Chemosensory Questionnaire (CSQ) has four questions each on smell and taste. A minimum score of 4 and a maximum of 20 for the smell scale and taste scale are possible with a higher score indicating better function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Speech Problems Assessed by Head and Neck Health Status Assessment Inventory (HNHSAI)</measure>
    <time_frame>2 years</time_frame>
    <description>The Head and Neck Health Status Assessment Inventory (HNHSAI) is a descriptive outcome assessment consisting of 14 yes/no questions to measure number of participants with speech problems.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Related Quality-of-Life Outcomes Using Validated Quality-of-Life Instrument EORTC QLQ-C30</measure>
    <time_frame>2 years</time_frame>
    <description>General quality of life is measured with the European organization for research and treatment of cancer (EORTC) quality of life questionnaire (QLQ) EORTC QLQ-C30 (cancer 30). They are self-administered questionnaires. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for the global health status / QoL represents a high QoL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Related Quality-of-life Outcomes Using Validated Quality-of-life Instrument EORTC-QLQ-H&amp;N</measure>
    <time_frame>2 years</time_frame>
    <description>General quality of life is measured with the European organization for research and treatment of cancer (EORTC) quality of life questionnaires (QLQ) for head and neck (H&amp;N) (EORTC-QLQ-H&amp;N). The head &amp; neck cancer module incorporates seven multi-item scales that assess pain, swallowing, senses (taste and smell), speech, social eating, social contact, and sexuality. There are also eleven single items. All of the scales and single-item measures range in score from 0 to 100. For all items and symptom scales, high scores represent a high level of symptomatology/problems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and Pattern of Locoregional Tumor Recurrence</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton/Photon Radiotherapy</intervention_name>
    <description>Given once a day, five days a week, for seven weeks.</description>
    <arm_group_label>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.</description>
    <arm_group_label>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
    <arm_group_label>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven greater than or equal to T2b and/or node positive non-metastatic,&#xD;
             squamous cell carcinoma of the nasopharynx, types WHO I-III.&#xD;
&#xD;
          -  No head and neck surgery of the primary tumor or lymph nodes except incisional or&#xD;
             excisional biopsies.&#xD;
&#xD;
          -  Zubrod performance status 0-1 or Karnofsky 70 or above.&#xD;
&#xD;
          -  All patients must undergo pre-treatment evaluation of tumor extent and tumor&#xD;
             measurement.&#xD;
&#xD;
          -  Nutritional and general physical condition must be considered compatible with the&#xD;
             proposed chemoradiation treatment&#xD;
&#xD;
          -  Patients must have adequate platelet and renal function as outlined in protocol.&#xD;
&#xD;
          -  18 years of age or above.&#xD;
&#xD;
          -  No active alcohol addiction.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IVC or evidence of distant metastases&#xD;
&#xD;
          -  Previous irradiation for head and neck tumor&#xD;
&#xD;
          -  Patient is on other experimental therapeutic cancer treatment&#xD;
&#xD;
          -  Other malignancy except non-melanoma skin cancer or carcinomas of head and neck origin&#xD;
             and have been controlled for at least 5 years.&#xD;
&#xD;
          -  Active untreated infection&#xD;
&#xD;
          -  Major medical or psychiatric illness&#xD;
&#xD;
          -  Prophylactic use of amifostine or pilocarpine&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy of grade 2 or greater by NCI CTCAE&#xD;
&#xD;
          -  Symptomatic altered hearing &gt; grade 2 by CTCAE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annie W Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <results_first_submitted>June 2, 2021</results_first_submitted>
  <results_first_submitted_qc>October 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2021</results_first_posted>
  <last_update_submitted>October 24, 2021</last_update_submitted>
  <last_update_submitted_qc>October 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Annie W. Chan, MD</investigator_full_name>
    <investigator_title>Annie W. Chan, MD</investigator_title>
  </responsible_party>
  <keyword>proton radiation</keyword>
  <keyword>photon radiation</keyword>
  <keyword>5-FU</keyword>
  <keyword>cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT00592501/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 9, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT00592501/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study period: 2006 and 2011 Location: Outpatient clinic at the Massachusetts General Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
          <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant found to have metastatic disease after enrollment thus deemed ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
          <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="32" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Toxicity</title>
        <description>Acute toxicities are side affects that occur during treatment and 90 days after completion.</description>
        <time_frame>54 days of chemoradiation treatment and 90 days after completion, up to 144 days total</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Toxicity</title>
          <description>Acute toxicities are side affects that occur during treatment and 90 days after completion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participant Compliance Rate to Assigned Treatment Intervention</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Compliance Rate to Assigned Treatment Intervention</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Received at least 2 cycles of concurrent chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received at least 2 cycles of adjuvant chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Received 3 cycles of concurrent chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sialometry to Evaluate Xerostomia (Dry Mouth)</title>
        <description>Sialometry is a measure of saliva flow. The normal daily production of saliva varies between 0.5 and 1.5 liters. Stimulated saliva is produced in response to a mechanical, gustatory, olfactory, or pharmacological stimulus, contributing to around 40-50% of daily salivary production. In adults, normal total stimulated salivary flow ranges 1-3 mL/minute, low ranges 0.7-1.0 mL/minute, while hyposalivation is characterized by a stimulated salivary flow &lt;0.7mL/minute.</description>
        <time_frame>Baseline and 2 years (24 months)</time_frame>
        <population>The mean values below are for all analyzed participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Sialometry to Evaluate Xerostomia (Dry Mouth)</title>
          <description>Sialometry is a measure of saliva flow. The normal daily production of saliva varies between 0.5 and 1.5 liters. Stimulated saliva is produced in response to a mechanical, gustatory, olfactory, or pharmacological stimulus, contributing to around 40-50% of daily salivary production. In adults, normal total stimulated salivary flow ranges 1-3 mL/minute, low ranges 0.7-1.0 mL/minute, while hyposalivation is characterized by a stimulated salivary flow &lt;0.7mL/minute.</description>
          <population>The mean values below are for all analyzed participants.</population>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unstimatulated saliva at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstimulated saliva at 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Penetration-aspiration Scale to Evaluate Swallowing Function</title>
        <description>The videofluoroscopic swallow study (VFSS) is the gold standard diagnostic tool to evaluate oropharyngeal dysphagia. The penetration-aspiration scale (PAS) is an 8-point scale used to grade the severity of penetration or aspiration observed in a videofluoroscopic swallow study. Aspiration is defined as the passing of the bolus below the true vocal folds, and penetration is when the bolus enters the airway but not below the true vocal folds. 1 is normal, no penetration or aspiration. 2-5 is penetration. 6-8 is aspiration.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Penetration-aspiration Scale to Evaluate Swallowing Function</title>
          <description>The videofluoroscopic swallow study (VFSS) is the gold standard diagnostic tool to evaluate oropharyngeal dysphagia. The penetration-aspiration scale (PAS) is an 8-point scale used to grade the severity of penetration or aspiration observed in a videofluoroscopic swallow study. Aspiration is defined as the passing of the bolus below the true vocal folds, and penetration is when the bolus enters the airway but not below the true vocal folds. 1 is normal, no penetration or aspiration. 2-5 is penetration. 6-8 is aspiration.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Penetration-aspiration scale at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Penetration-aspiration scale at 12 months after radiation therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="1.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serial Measurements of Maximal Inter-incisal Distance to Evaluate Trismus (Lockjaw)</title>
        <description>Serial measures of the changes of the maximal inter-incisal distance in the vertical opening, right lateral, and left lateral jaw movements are used to evaluate trismus (lockjaw). An average measurement of the three directional areas will be reported.</description>
        <time_frame>Baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Serial Measurements of Maximal Inter-incisal Distance to Evaluate Trismus (Lockjaw)</title>
          <description>Serial measures of the changes of the maximal inter-incisal distance in the vertical opening, right lateral, and left lateral jaw movements are used to evaluate trismus (lockjaw). An average measurement of the three directional areas will be reported.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maximal inter-incisal distance at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal inter-incisal distance at 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ChemoSensory Questionnaire (CSQ) to Evaluate Smell and Taste Function</title>
        <description>The Chemosensory Questionnaire (CSQ) has four questions each on smell and taste. A minimum score of 4 and a maximum of 20 for the smell scale and taste scale are possible with a higher score indicating better function.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>ChemoSensory Questionnaire (CSQ) to Evaluate Smell and Taste Function</title>
          <description>The Chemosensory Questionnaire (CSQ) has four questions each on smell and taste. A minimum score of 4 and a maximum of 20 for the smell scale and taste scale are possible with a higher score indicating better function.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Taste score post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smell score post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Speech Problems Assessed by Head and Neck Health Status Assessment Inventory (HNHSAI)</title>
        <description>The Head and Neck Health Status Assessment Inventory (HNHSAI) is a descriptive outcome assessment consisting of 14 yes/no questions to measure number of participants with speech problems.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Speech Problems Assessed by Head and Neck Health Status Assessment Inventory (HNHSAI)</title>
          <description>The Head and Neck Health Status Assessment Inventory (HNHSAI) is a descriptive outcome assessment consisting of 14 yes/no questions to measure number of participants with speech problems.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Health Related Quality-of-Life Outcomes Using Validated Quality-of-Life Instrument EORTC QLQ-C30</title>
        <description>General quality of life is measured with the European organization for research and treatment of cancer (EORTC) quality of life questionnaire (QLQ) EORTC QLQ-C30 (cancer 30). They are self-administered questionnaires. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for the global health status / QoL represents a high QoL.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality-of-Life Outcomes Using Validated Quality-of-Life Instrument EORTC QLQ-C30</title>
          <description>General quality of life is measured with the European organization for research and treatment of cancer (EORTC) quality of life questionnaire (QLQ) EORTC QLQ-C30 (cancer 30). They are self-administered questionnaires. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for the global health status / QoL represents a high QoL.</description>
          <units>Global Health Status score on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Health Related Quality-of-life Outcomes Using Validated Quality-of-life Instrument EORTC-QLQ-H&amp;N</title>
        <description>General quality of life is measured with the European organization for research and treatment of cancer (EORTC) quality of life questionnaires (QLQ) for head and neck (H&amp;N) (EORTC-QLQ-H&amp;N). The head &amp; neck cancer module incorporates seven multi-item scales that assess pain, swallowing, senses (taste and smell), speech, social eating, social contact, and sexuality. There are also eleven single items. All of the scales and single-item measures range in score from 0 to 100. For all items and symptom scales, high scores represent a high level of symptomatology/problems.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality-of-life Outcomes Using Validated Quality-of-life Instrument EORTC-QLQ-H&amp;N</title>
          <description>General quality of life is measured with the European organization for research and treatment of cancer (EORTC) quality of life questionnaires (QLQ) for head and neck (H&amp;N) (EORTC-QLQ-H&amp;N). The head &amp; neck cancer module incorporates seven multi-item scales that assess pain, swallowing, senses (taste and smell), speech, social eating, social contact, and sexuality. There are also eleven single items. All of the scales and single-item measures range in score from 0 to 100. For all items and symptom scales, high scores represent a high level of symptomatology/problems.</description>
          <units>dry mouth score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate and Pattern of Locoregional Tumor Recurrence</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
            <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Pattern of Locoregional Tumor Recurrence</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local recurrence in high-dose region</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distant recurrence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Toxicity evaluation occurred during protocol therapy and 5+ years of follow-up.</time_frame>
      <desc>Adverse events were routinely collected through regular investigator assessment and regular laboratory testing.</desc>
      <group_list>
        <group group_id="E1">
          <title>Proton/Photon Radiotherapy, Cisplatin, Fluorouracil</title>
          <description>Proton/Photon Radiotherapy: Given once a day, five days a week, for seven weeks.&#xD;
Cisplatin: Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.&#xD;
Fluorouracil: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/bone marrow</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <description>Neutropenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <description>ANC increased</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>Anemia (hemoglobin decreased)</description>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - Other</sub_title>
                <description>Hemorrhage unspecified</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <description>leukocytes decreased</description>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow - Other</sub_title>
                <description>Pancytopenia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <description>platelets decreased</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac troponin T (cTnT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vasovagal episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients with/without baseline audiogram and enrolled in a monitoring program</sub_title>
                <description>Hearing loss</description>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Auditory/Ear - Other</sub_title>
                <description>ear fullness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="29" subjects_affected="14" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, high (hyperthyroidism, thyrotoxicosis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thyroid function, low (hypothyroidism)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia/ diplopia (double vision)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <description>acid reflux</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="21" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Salivary gland changes/saliva</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="35" subjects_affected="20" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Taste alteration (dysgeusia)</sub_title>
                <counts group_id="E1" events="33" subjects_affected="20" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" events="61" subjects_affected="22" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <description>Soft palate defect</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ileus, GI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis - oral cavity</sub_title>
                <description>thrush/oral mucositis</description>
                <counts group_id="E1" events="38" subjects_affected="17" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis - pharynx</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="55" subjects_affected="21" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <description>Odynophagia</description>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dry mouth/salivary gland (xerostomia)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="33" subjects_affected="19" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <description>Soft palate fusion to post-oropharynx</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <description>&quot;jittery&quot;</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <description>Carboplatin extravasation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Lymphatics - other</sub_title>
                <description>Edema unspecified</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Edema: head and neck</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="63" subjects_affected="22" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain - head/headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain - extremity-limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <description>mucositis unspecified</description>
                <counts group_id="E1" events="36" subjects_affected="19" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain: oral-gums</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pain - other</sub_title>
                <description>pain at g-tube site</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - anus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - back</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - other</sub_title>
                <description>ear pain unspecified</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - middle ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - chest wall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - oral cavity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - throat/pharynx/larynx</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>pain - joint</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="49" subjects_affected="22" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms - Other</sub_title>
                <description>thick mucus, unspecified</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - lung (pneumonia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infection - other</sub_title>
                <description>Candidiasis</description>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infections - skin (cellulitis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <description>c diff</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infection - Middle ear (otitis media)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>infection - bronchus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>infection - upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Infection - Other</sub_title>
                <description>ear infection unspecified</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <description>Alkaline phosphatase increased</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ALT, SGPT</sub_title>
                <description>ALT increased</description>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <description>AST increased</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum-low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Calcium, serum-high (hypercalcemia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low (hypokalemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low (hypomagnesemia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low (hyponatremia)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <description>&quot;increased transaminase/LFT&quot;</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high (hyperkalemia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high (hypernatremia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis (non-septic)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <description>neck stiffness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Trismus (difficulty, restriction or pain when opening mouth)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <description>restless leg syndrome</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS necrosis/cystic progression</sub_title>
                <description>CNS necrosis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neurology - other</sub_title>
                <description>Dysosmia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Extrapyramidal/ involuntary movement/restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <description>neuropathy unspecified</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>neurology - other</sub_title>
                <description>peripheral neuropathy unspecified</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Speech impairment (e.g., dysphasia or aphasia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <description>acute renal failure</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary - Other</sub_title>
                <description>renal insufficiency</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <description>hoarseness</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory - nose</sub_title>
                <description>Epistaxis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hiccoughs (hiccups, singultus)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <description>nasal congestion</description>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <description>Nasal Stenosis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <description>Pneumomediastinum</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <description>Rhinorrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <description>desquamation</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <description>Erythema unspecified</description>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <description>Sebaceous Cysts</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin --Other</sub_title>
                <description>Skin breakdown - lips</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <description>rash unspecified</description>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Rash: dermatitis associated with radiation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <description>DVT: left leg</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <description>Thromboplebitis (left arm)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Annie W. Chan, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-5184</phone>
      <email>AWCHAN@PARTNERS.ORG</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

